Is sec­ond time the charm for ozan­i­mod? Cel­gene starts to find out with EMA fil­ing

7 years ago
Pharma

Take­da touts a land­mark head-to-head PhI­I­Ib win over Hu­mi­ra; Al­ler­gan's oral CGRP is now un­der FDA re­view

7 years ago
News Briefing

Prin­cip­ia, Ab­b­Vie walk away from 2017 part­ner­ship for in­flam­ma­to­ry, au­toim­mune drugs

7 years ago
Pharma

Two big phar­ma ex­ecs share the same chal­lenges, but com­pen­sa­tion? They’re not even close

7 years ago
People

It’s what Bris­tol-My­ers ex­ecs aren’t say­ing that makes one key an­a­lyst won­der about a po­ten­tial buy­out of­fer, ...

7 years ago
Deals

Roche claims a first in breast can­cer as Tecen­triq/Abrax­ane com­bo nabs quick ap­proval in front­line use

7 years ago
Pharma

Ear­ly da­ta snap­shots of Ax­o­van­t's gene ther­a­pies for Parkin­son's, Tay Sachs ap­pear promis­ing

7 years ago
R&D
Cell/Gene Tx

Lund­beck fund backs a $50M launch round for SNIPR Bio­me, a new brand of CRISPR Cas biotech

7 years ago
Financing
Startups

Prison of­fi­cials launch a probe in­to Mar­tin Shkre­li's lat­est an­tics, al­leged­ly run­ning his biotech busi­ness with a ...

7 years ago
People

Mer­ck gives King's Col­lege Lon­don, Well­come Trust up to $340M in deal to de­vel­op non-opi­oid painkillers

7 years ago
Discovery

From Agios to De­ci­phera, Steve Ho­ert­er plots an­oth­er on­col­o­gy launch; Roche ex­ec Chris­tiane Hamachar moves to In­dia ...

7 years ago
Peer Review

Dupix­ent scores speedy re­view for rhi­nos­i­nusi­tis with nasal polyps; Af­ter trans­plant, third pa­tient is HIV-free for 3 ...

7 years ago
News Briefing

Years af­ter it was OK'd, AM­AG's drug for pre­vent­ing preterm births fails bad­ly in long-await­ed con­fir­ma­to­ry tri­al

7 years ago
R&D

FDA ex­perts gun down a big part of Sanofi's pitch for their con­tro­ver­sial vac­cine

7 years ago
Pharma

The Fort Dix re­demp­tion: Mar­tin Shkre­li’s con­tra­band cell phones, new biotech schemes and fresh so­cial me­dia in­famy

7 years ago
People

Key pos­i­tive da­ta on month­ly HIV reg­i­men of­fer hope for pa­tients sad­dled with stan­dard dai­ly pills

7 years ago
R&D

FDA re­vers­es course, de­cides not to add suf­fix­es to old­er bi­o­log­ics’ non­pro­pri­etary names

7 years ago
Pharma

'We can't': Jeff Lei­den stands his ground as MPs grill Ver­tex on pric­ing dis­agree­ment with NHS

7 years ago
Pharma

Brig­gs Mor­ri­son’s lit­tle biotech Syn­dax con­cedes 2 key tri­al set­backs for its lead drug, as shares shriv­el some ...

7 years ago
R&D

Brent Saun­ders’ team gets hit with a PhI­II dis­as­ter — and a grow­ing mob of Al­ler­gan crit­ics seizes the mo­ment

7 years ago
R&D

FDA pins an­oth­er 'break­through' badge on Ab­b­Vie's vene­to­clax; Ex­press Scripts bats back at drug­mak­ers on pric­ing

7 years ago
News Briefing

Jeff Mar­raz­zo sparked a bid­ding war for Spark that spurred a thrifty Roche CEO to seal the win­ning deal with a ...

7 years ago
Deals

Pri­vate on­col­o­gy out­fit Onc­ter­nal us­es GTx as shell to make Nas­daq de­but

7 years ago
Pharma

CAR-T shows promise for lu­pus in mouse study — will it in­spire hope in a be­lea­guered field?

7 years ago
Discovery
First page Previous page 953954955956957958959 Next page Last page
A service from the Financial Times